Flamel Technologies Sa (FLML) Files Form 4 Insider Selling : Francis Fildes Sells 15,000 Shares

Flamel Technologies Sa (FLML): Francis Fildes , director of Flamel Technologies Sa sold 15,000 shares on Sep 22, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $13.45 per share for a total value of $201,750.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 7, 2016, Michael S Anderson (CEO) purchased 2,000 shares at $14.12 per share price.On Sep 6, 2016, Craig R Stapleton (director) purchased 10,000 shares at $13.52 per share price.Also, On Mar 22, 2016, Phillandas T. Thompson (officer ) purchased 10,000 shares at $11.10 per share price.On Mar 21, 2016, Sandra L Hatten (Sr. VP, Quality & Reg Affairs) purchased 3,000 shares at $11.01 per share price.

Flamel Technologies S.A. (ADR): On Thursday, Sep 22, 2016 heightened volatility was witnessed in Flamel Technologies S.A. (ADR) which led to swings in the share price. The shares opened for trading at $13.79 and hit $13.94 on the upside , eventually ending the session at $13.73, with a gain of 0.66% or 0.09 points. The heightened volatility saw the trading volume jump to 91,320 shares. The 52-week high of the share price is $24.95 and the company has a market cap of $566 M . The 52-week low of the share price is at $7.56.

Flamel Technologies S.A. (ADR) Money Flow Index Chart

Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate) a non-selective antagonist of Beta 1 Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Leave a Reply

Flamel Technologies S.A. (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Flamel Technologies S.A. (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.